Compare Diamondback Energy Inc (FANG) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs Heron Therapeutics Inc — how do they compare? Diamondback Energy Inc trades at $192.13 (market cap $53.67B), while Heron Therapeutics Inc trades at $0.41 (market cap $68.01M). The key difference: Diamondback Energy Inc is far larger — about 789.1× Heron Therapeutics Inc's market cap, and Diamondback Energy Inc pays a 2.3% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Diamondback Energy Inc for 69 Days and Heron Therapeutics Inc for 35 Days on average.
| FANG | HRTX | |
|---|---|---|
Market Cap | $53.67B | $68.01M |
Volume | 2,250,644 | 1,891,941 |
Sector | Energy | Health |
52-Week High | $213.69 | $1.49 |
52-Week Low | $137.29 | $0.27 |
Typical Hold Time | 69 Days | 35 Days |
Enterprise Value | $65.83B | $174.75M |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $191.68, up 3.96% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with revenue growth from $14.93B in 2025 to projected $17.0B in 2026, though net margins have compressed. Recent earnings beat expectations in Q1 and Q2 2026, while technical indicators show the stock trading near pivot point resistance at $191 with overall bullish moving average signals.
FANG presents a compelling investment case with 91% analyst buy ratings and a $231.77 price target offering 21% upside. Key opportunities include strong Permian Basin positioning and dividend growth, while risks include oil price volatility and insider selling activity. The company's solid cash flow generation supports continued shareholder returns despite margin pressure from rising costs.
Heron Therapeutics (HRTX) trades at $0.36, down 8.15% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst sentiment remains overwhelmingly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings call discussions.
HRTX presents a high-risk opportunity with strong analyst support but fundamental challenges. The bullish technical setup and institutional confidence contrast with persistent losses and negative cash flow from operations. Investors face upside from potential operational improvements against the risk of continued financial underperformance in the competitive biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
